Objective: A consumer-oriented efficacy assessment in clinical trials should measure changes in chief complaint and consumer request (symptoms of most concern to patient/caregiver), which may be diluted in change scores of multisymptom scales. Method: In the Research Units on Pediatric Psychopharmacology (RUPP) Autism Network 8-week double-blind trial of risperidone versus placebo, the chief concerns of parents were collected at 0, 4, and 8 weeks (endpoint), in addition to standardized primary measures. Blinded clinical judges rated change from baseline to 4 and 8 weeks on a 9-point scale (1 = normalized, 5 = unchanged, 9 = disastrous); 94 participants had usable data. Results:
vidualized estimate of change on a clinician-rated 7-point scale, on which the two highest ratings of improvement are customarily considered a "response" to treatment, making a categorical binary measure. Though these two measures together (one dimensional, the other categorical, one rated by patient or caregiver, one by clinician) are accepted as providing a reasonable profile of outcome in clinical trials, they may not be complete, the most sensitive, or the most consumeroriented (i.e., indicative of the patient's or family's requested relief) measurement.
Even in clinical practice, Lazare et al. (1975) and Eisenthal and Lazare (1976) argued that diagnostic formulations and treatment plans often do not adequately address the patient's (or family's) request or chief complaint. They advocated a "customer approach to patienthood" that considers not only diagnosis but also the patient's request. This request, which is often implied in the chief complaint, may not neatly fit under a standard diagnosis (Arnold and Jensen, 1998) . The danger of failing to consider the patient's presenting complaint/request would seem to apply even more strongly to assessment in clinical trials, which relies so heavily on standardization. Standardized scales may include items of little relevance to a particular patient, thus diluting their sensitivity. Moreover, they may not even contain the exact item(s) of most concern to the patient or caretakers, conceptualized from the consumer's perspective. Thus, standardized scales may fail to reflect real change important to the individual family. Although the CGI attempts to consider all available information in each individual, it has the disadvantage of being filtered through the clinician's values, thus perhaps not fully weighting the problem of concern to the patient or caretaker. Also, with its customary binary analysis, the CGI does not provide the power of a dimensional analysis. Further, neither measure allows a convenient consensus or collegial check on the rating for an individual patient. Another approach to obtaining more individualized and ecologically valid outcome measures is behavior counts by trained observers of videotaped behavior samples. This strategy has limitations of practicality, expense, and limited sampling frame.
To address some of these shortcomings, the assessment instruments of the RUPP risperidone study in autistic disorder (RUPP Autism Network, 2002) included, besides the two primary measures (standardized ABC and CGI-I), an individualized target symptom assessment. This approach was originally described by Arnold et al. (1972) , was used in subsequent studies in attention-deficit/hyperactivity disorder (Arnold et al., 1976 (Arnold et al., , 1978 , and was further refined for the RUPP autistic disorder risperidone trial. In the current refinement, behavior quantifications of the concern of the caregiver (request for relief related to "chief complaint") were collected by the blinded clinicians who did the CGIs but were rated for outcome by other blinded clinical judges on a 9-point scale of change relative to baseline. This strategy provided a blinded third-party rating in addition to the parent rating on the ABC and the clinician rating on the CGI. This paper reports the reliability and outcomes of this simple measure in the RUPP risperidone trial, compares it to the primary measures, and explores clustering of specific target symptoms as a measure of parental concerns. The three main hypotheses were that target symptom measurements would be reliable (as shown by intraclass correlation of 0.8 or more); would be collinear with the two primary outcome measures of the study (i.e., ABC Irritability subscale and CGI-I), showing convergent validity; and would be as statistically sensitive as the primary measures (as shown by finding treatment effects with a statistical significance level at least equal to those of the primary outcome measures). Additional exploratory analyses included comparing the effect size of target symptoms to the effect size of the standard dimensional scale and exploring the agreement with other methods of defining responder status.
METHOD
The RUPP Autism Network's first study (RUPP Autism Network, 2002 ) was a double-blind comparison of risperidone (n = 49) to placebo (n = 52) for 8 weeks, with clinical adjustment of dosage in the first 4 weeks. The sample included children and adolescents age 5 to 17 (mean 8.8 years) with autistic disorder and irritability, self-injurious behavior, and/or aggression. Three risperidone and 12 placebo subjects terminated prematurely for lack of efficacy and 6 additional placebo subjects for other reasons. Primary intention-totreat analyses with last observation carried forward for all randomized subjects showed a highly significant benefit for risperidone on both the ABC Irritability subscale (57% decrease versus 14% decrease) and the CGI-I (75% versus 11% with CGI-I ≤2). The effect size (Cohen's d) on the ABC Irritability subscale was 1.2 at 8 weeks.
At baseline, 4 weeks, and 8 weeks, the same blinded clinician who did the CGI interviewed the parent and recorded a behavioral description and quantification of the one or two problems of greatest concern to the parent. At baseline, the symptoms were elicited with the question, "What one or two problems are you most concerned about for your child?" Most parents designated two. Once chosen at baseline, the same target symptoms were retained throughout. Description of the symptoms included frequency, duration, or time spent on it and intensity, interference with daily function or family life, and other salient consequences (e.g., extent of injury, amount of damage, inability to go to store or restaurant, need to lock doors), elicited by specific questions if necessary ("How often?" "How long each time?" "How many hours a day?" "How does it interfere with daily activities?"). Examples of target symptom descriptions are: 1. "Stereotypic finger movements in front of face hundreds of times a day, each episode a few seconds to 5 minutes. Cannot go 30 minutes without. Interferes with schoolwork." 2. "Tantrums twice a day lasting 10-25 min. each, throwing self on floor, flailing arms, breaking furniture, hurting other child if in way, incidental damage to self. Parents won't take out in public." Follow-up after 4 or 8 weeks on risperidone for these same symptoms was elicited by a statement such as, "Before starting the treatment, you said you were concerned about finger movements in front of his face and tantrums. How have those been the last couple of weeks?" If not spontaneously reported, the usual questions about frequency, duration, and consequences were repeated, resulting in something like this: 1. "Stereotypic finger movements 20-40 times a day, a few seconds each time. Went 2 hours without while interested in movie. Now able to do schoolwork." 2. "Tantrum twice in past week, lasting about 5 min., stomping and screaming without damage or injury. Stays off floor. Parents now willing to take out." Semistructured elicitation and recording of such descriptions averaged about 5 to 10 minutes. After all data were thus collected, a panel of blinded clinical judges drawn from all sites reviewed and rated these quantified behavioral descriptions. Each judge rated each target symptom independently and the ratings were statistically averaged. Such rating takes 2 to 4 minutes per case once the judge/rater is experienced. The baseline description was identified for each subject, and the other descriptions were rated in reference to the baseline on the following scale: 1 = normal; 2 = markedly improved; 3 = definitely improved; 4 = equivocally improved; 5 = no change; 6 = equivocally worse; 7 = definitely worse; 8 = markedly worse; 9 = disastrously worse (e.g., had to be hospitalized). In this study, the target symptoms were blindly rated on this 9-point scale by five clinical experts who were not involved in the collection of the target symptom quantified descriptions, thus providing ratings by a third party (in addition to parent ratings and clinician-rated CGI).
Analysis
Ratings were averaged for each patient over target symptoms (each patient had one or two target symptoms) and the five raters. Averages were calculated for each patient separately at weeks 4 and 8. These case averages were used to calculate means for the primary dimensional group comparisons. For exploratory binary analysis, the case average rating was dichotomized at a cut-point of 3.0, with 3 or less indicating a responder.
Reliability of the dimensional measure was estimated separately at weeks 4 and 8 using an intraclass correlation coefficient. Components of variance included random effects for patient, rater, and error. Reliability is reported for a single rating for each patient and for the average of ratings over raters (Spearman-Brown step-down reliability; Brown, 1996) . Reliability of the dichotomous measure was estimated at week 8 using Cohen's κ statistic.
Treatment effects for average target symptom ratings and ABC Irritability subscales were analyzed in parallel on the patients who had complete data for each outcome measure. We estimated a mixed effects linear model: fixed effects were treatment, time, and treatment by time interaction, and random effects were patient and error. Effect sizes were estimated using Cohen's standardized difference in means (d).
To check convergent validity and collinearity with the study's primary outcome measures, the target symptom ratings were correlated with the ABC Irritability subscale (Pearson r) and with the dichotomized CGI-I (point biserial correlation).
Target symptoms were consensually classified by two child psychiatrists into seven categories: aggression to others; self-injurious behavior; property destruction; tantrums; yelling/screaming; stereotypy; and hyperactivity/impulsivity/agitation. Whenever possible, the symptom was assigned to only one category, but for two symptoms it seemed most logical to assign them to two categories. In this analysis, the two target symptoms of a subject were considered separately. Patients with each type of symptom were compared on risperidone/placebo differences.
Although the target symptom rating was used only dimensionally in previous research (Arnold et al., 1972 (Arnold et al., , 1976 (Arnold et al., , 1978 , we decided also to explore classifying clinical response by categorical cut-score. We used a mean of 3.0 or less, corresponding to a rating of "definitely improved" or better, to define positive response ("responders"). The target symptom method of classifying positive response was compared to our primary, already published methods of defining positive response. These include the standard cut-score on the CGI-I of 2 or less (much or very much improved) and the more rigorous combined criterion of a 25% decrease on the ABC Irritability subscale score coupled with the standard cut-score on the CGI-I (RUPP Autism Network, 2002). To evaluate any disagreement in classification, we conducted McNemar tests with the target symptom method against each of the other methods (the CGI-I alone or the more rigorous combined criterion).
RESULTS
There were 94 cases (47 each treatment) with usable data, 87 at each time point. At week 8, there were 44 from the risperidone group and 43 from the placebo group. Seven cases had no target symptom data due to a misunderstanding in data collection early in the study (a new target symptom was elicited rather than new description of the original symptom selected at baseline). Table 1 shows that the intraclass correlation among the five raters was 0.895 at both week 4 and week 8. The Spearman-Brown step-down reliability (Brown, 1996) for the average of five raters was 0.974 at week 4 and 0.976 at week 8. Thus reliability approached 0.9 even if only one rater were used and exceeded 0.97 for the mean of the five raters in this study. The components of variance confirm reliability: low rater variance suggests that raters were interchangeable, high patient variance confirms enough variance in the data to allow raters to disagree and create "noise," and the low error variance shows that they did not.
At week 8, ratings for target symptom 1 and symptom 2 correlated (Pearson r) with each other at 0.76, with the Irritability subscale of the ABC at 0.64 and 0.55 respectively, and with the CGI-I at 0.75 and 0.68 respectively. These were comparable to the correlation of CGI-I with the ABC Irritability subscale, 0.60 in the same subjects. All of these correlations were significant at p < .0001. Table 2 shows the target symptom score means by treatment and week. At both week 4 and week 8, the risperidone/placebo difference was highly statistically significant (p < .001), at a level comparable to that detected on the primary outcome measures of the RUPP autism risperidone study (RUPP Autism Network, 2002) . The effect size at week 8, end of treatment, was d = 1.39, nominally higher than the 1.22 for the ABC Irritability subscale for the same participants. The placebo score, 4.5, was between "no change" and "equivocal improvement." The risperidone score, 2.8, was between "definite improvement" and "marked improvement." The treatment by time interaction was also significant at p < .001, indicating that the risperidone group improved from week 4 to week 8 while the placebo group deteriorated between week 4 and week 8 (presumably following an initial mild placebo response from baseline to week 4).
The number of parents citing each category of symptoms is shown in Table 3 , with the means for placebo and risperidone on the respective symptoms. In an exploration of possible differential effects on the behavior categories, each of the behavior categories had the same placebo/risperidone comparison repeated as for the whole-sample means. Because of reduced power from smaller numbers, two of the seven individual categories of symptoms did not show a significant difference between placebo and risperidone, though the trend was in the same direction as both the overall sample and the categories showing significance (risperidone superior to placebo). The hypothesized power problem was tested by collapsing the two nonsignificant small categories "property destruction" and "yelling/screaming" and analyzing them as a single category, which yielded statistical significance. The effect size (Cohen's d) varied more than twofold across categories, from 2.11 for selfinjurious behaviors to 0.87 for property destruction. Self-injurious behaviors showed more improvement on risperidone relative to placebo from week 4 to week 8 than did the other categories (significant interaction of time and category).
Using the cut-score of 3.0 or less ("definitely improved" or better) to define positive response, we clas- Note: Means shown are averaged over one or two target symptoms for each subject. a Raw changes (SD) for the Aberrant Behavior Checklist (ABC) Irritability subscale were as follows: risperidone −11.54 (8.82) at 4 weeks, −14.57 (10.24) at 8 weeks; placebo −6.15 (6.99) at 4 weeks, −3.88 (7.90) at 8 weeks.
* Treatment and treatment-by-time interactions were significant at p < .001 (i.e., risperidone was significantly superior to placebo and the superiority was significantly greater at 8 weeks than at 4 weeks). sified 21% (9/43) of the placebo group versus 70% (31/44) of the risperidone group as clinical responders (Table 4) . We compared this classification with the two primary methods. When compared to the CGI-I score of 2 or less (much or very much improved) at week 8, positive response on the target symptom rating showed good agreement (κ coefficient = 0.61), with no systematic difference between methods (McNemar test = 0.0, p = 1.0). Similarly, when compared to the combination of 25% decrease in ABC Irritability subscale plus a CGI-I of 2 or less, the κ value was 0.67, indicating good agreement, with the McNemar test again insignificant. Thirty-eight of the 43 subjects in the placebo group were classified identically by both the target symptom rating and the primary outcome algorithm (25% reduction in ABC Irritability subscale plus CGI-I ≤2): 33 of 43 placebo nonresponders and 5 of 43 placebo responders. Similarly, 35 of 44 in the risperidone group were classified identically by both methods: 27 of 44 risperidone responders and 8 of 44 nonresponders.
Although the overlap of responders by target symptom cut-score and by the primary outcome algorithm was highly significant (p < .001), it was not complete.
The target symptom cut-score of 3.0 or less classified four placebo and four risperidone participants as "responders" that were not identified by the primary algorithm, and the primary algorithm identified one placebo and five risperidone responders not so classified by the target symptom cut-score. Thus, 5 of 43 placebo participants and 9 of 44 risperidone participants were classified as responders by only one method.
The categorical comparisons provide an opportunity for speculative proxies of classical validity data. In Table 4 , if the primary algorithm classification of response is taken as gold standard caseness (38 "cases" in 87), then the target symptom true-positive rate would be 32 of 87 (37%), the false-positive rate 8 of 87 (9%), the true-negative rate 41 of 87 (47%), the falsenegative rate 6 of 87 (7%), sensitivity 32 of 38 (84%), specificity 41 of 49 (84%), positive predictive power 32 of 40 (80%), and negative predictive power 41 of 47 (87%). Alternatively, if one takes convergent validity of the two methods as gold standard (32 "cases" of response in 87), then for the primary algorithm the false-positive rate is 6 of 87 (7%), specificity 49 of 55 (89%), positive predictive power 32 of 38 (84%), and negative predictive power 49 of 55 (89%) and for tar- Note: Primary ITT algorithm = CGI ≤2 plus decrease of 25% in ABC Irritability subscale at 8 weeks. Target symptom rating cutscore is ≤3 on the case mean rating at 8 weeks. ITT = intention-to-treat; CGI = Clinical Global Impression; ABC = Aberrant Behavior Checklist. get symptoms, the false-positive rate is 8 of 87 (9%), specificity 47 of 55 (85%), positive predictive power 32 of 40 (80%), and negative predictive power 47 of 55 (85%).
DISCUSSION
These analyses yield additional significant placebocontrolled evidence for the short-term benefit of risperidone for children with irritable, aggressive, selfinjurious behavior associated with autistic disorder, using a third rater (besides the parent who filled out the ABC and the blinded clinician who rated the CGI). The results also demonstrate the reliability, validity, and usefulness of a standardized approach to assessing chief complaints and requested behavior changes by parents of children with serious behavioral problems. The target symptom assessment proved to be practical, reliable, and sensitive to change. Its validity is supported by the fact that it was highly convergent with both of the primary outcome measures, the standardized ABC Irritability subscale score and the CGI. Its sensitivity to change with treatment is demonstrated by its effect size (1.4 compared to 1.2 for the ABC Irritability subscale score at treatment endpoint). Thus, target symptom assessment combines some of the best qualities of a dimensional scale and the clinically flexible CGI, with the added advantage of consumer sensitivity and rating by a blinded third party.
This was not a consumer satisfaction survey; it did not ask for parent subjective ratings about the treatment received. Rather, we collected quantified behavioral reports from parents, which were rated by blinded clinical judgment. In fact, one of its advantages was that it corrected for parental rating bias, in which parents of very troubled children have been so numbed by their stressful experience that they accept highly deviant behavior as normal. With this technique, they merely supplied quantified specifics, which were judged by impartial raters. Nevertheless, the primary advantage of target symptom measurement is that it automatically adjusts to the concerns of the patient or family. In contrast, a standard scale selected by informed clinical intuition, precedent, and previously demonstrated sensitivity may miss the mark for a particular case. Additionally, target symptom assessment can enhance the value of the study results by providing detailed information about the specific complaints of the study participants as well as quantified assessment of treatment effects on these complaints. It can shed some light on which of the various symptoms targeted are most responsive to the treatment. Interestingly, in this study most target symptoms strikingly resembled subscale items from the ABC. The target symptoms complement the broad standard scale by providing more personalized assessment. Finally, this approach to eliciting and documenting chief complaints may be useful in clinical practice as a way to quantify symptom severity and treatment effects at the individual level.
The exploration of using a cut-score for a categorical definition of clinical responder confirms the extensive but incomplete overlap of the target symptom assessment with the primary measures. The incomplete overlap, of course, is one value of the target symptom assessment, picking up responses missed by the traditional methods. The target symptom cut-score appeared nominally a bit weaker than the primary outcome algorithm in detecting categorical response in the risperidone rather than placebo group. Although the treatment contrast was still impressive, the strength of target symptom assessment for clinical trials appears to lie more with its original dimensional use rather than categorical use.
Whether target symptom assessment might be used dimensionally as a primary clinical trial outcome measure remains to be determined, partly based on how collinear it would be with other scales used to measure other symptoms of other disorders. The collinearity with the ABC Irritability subscale score was probably specific to the population sampled in this study. This convergence between the target symptoms and the Irritability subscale suggests that the latter was indeed a good choice for the primary outcome measure in this study. We presume, for example, that target symptoms collected from a depressed or anxious sample would correlate highly with depression or anxiety scales, not the ABC. Based on its ability to consider individualized treatment goals, target symptom assessment can be at least an enlightening secondary measure and can help confirm the validity and consumer responsiveness of the primary measures, especially in phase IV clinical trials.
Target symptom assessment bears some similarity to the more complex goal attainment scaling (e.g., Newton, 2002) in that both involve issues selected by the patient or parent, emphasize objective behavioral quantification, are used as outcome measures, and are collinear with other measures. Differences include that target symptom assessment is simpler, more easily learned, restricted to two symptoms, focused on problems, entirely evaluative (not incorporated into treatment process), and rated retrospectively by blinded clinicians in comparison to baseline, whereas goal attainment scaling requires up to 2 hours to learn, may involve more than two goals, focuses mainly on positive achievements, is part of the treatment/rehabilitation/education process with prospective establishment of expected goals to be attained, and is rated by the patient on a scale compared to expected goal attainment rather than to baseline.
Limitations
Any comparisons between categories of target symptoms regarding the amount of placebo-controlled improvement must be tempered with recognition that the categories were self-selected by the case, and any comparison is not protected by randomization (i.e., the categories may be biased by self-selection, possibly differing at baseline in many ways). In comparisons, one can only say that these were the results for subjects whose parents considered these specific symptoms paramount; for instance, participants whose parents considered tantrums to be of most concern had improvement of d = 1.95 in that symptom, whereas those whose parents considered stereotypy of most concern had improvement of only d = 1.01 in their symptom. The practical clinical value of this example is that when a clinician is faced with a chief complaint of tantrums, there is more chance of a satisfactory result from risperidone than if the chief complaint is stereotypy.
Like the CGI and ABC Irritability subscale used as the major outcome measures for this study, the target symptom assessment did not consider side effects. (The CGI was done by a blinded clinician who did not know about side effects, which were tracked separately by the primary clinician.) Thus, this limitation equally affected all three measures.
Another limitation is that the parent is an informant for all three measures: ABC, CGI, and target symptom, so the informant might account for the significant collinearity and convergent validity. However, there are subtle differences in how the information is filtered. The ABC is parent subjective rating. The CGI takes information from parent, teacher, and observation of the child at the visit and synthesizes it through the filter of the clinician's judgment. The target symptom rating takes quantified descriptions of behavior (not subjective ratings) from the parent and uses them for blinded clinician ratings with high reliability. Thus, only the ABC relies on parent subjective judgment.
The clear results obtained in this study of risperidone for irritability/aggression in autistic disorder and in previous studies of stimulants for attentiondeficit/hyperactivity disorder (Arnold et al., 1972 (Arnold et al., , 1976 (Arnold et al., , 1978 may not generalize to studies in other disorders or with other treatments. Both of these disorders have easily observable behavior and show large effect sizes (on both standardized scales and target symptom assessment) for the respective treatment. In disorders with smaller treatment effect sizes or less easily observable target symptoms, the target symptom assessment may not be as sensitive relative to standardized scales as it is for these two disorders. On the other hand, target symptom assessment may have an advantage for hard-to-detect small treatment effects and may find its greatest utility in such disorders. A related caution is that patients or parents may choose neither a symptom of the disorder nor anything susceptible to treatment effect. Even this, of course, may be useful information, questioning the relevance of the diagnosis and/or treatment to the patient. Whether target symptom assessment is more or less applicable to other disorders and other treatments can be answered only by empirical trials, and we urge other investigators to experiment with this simple additional assessment in their next clinical trial.
Although target symptom assessment performed very well with dimensional analysis, the results as a binary categorical measure were less impressive. Because of the multiple judges, leading to intervallike scaling of means, we were able to analyze with parametric statistics. With only a single judge, such as in the clinical setting, the only possible ratings would be integers, resulting in ordinal scaling or classification, which would be less powerful. Therefore, for clinical trial group comparisons, we recommend using mean ratings of multiple blinded judges of each target symptom, as we did. We found this practical (a half-day's work for each judge to rate all cases), and using a judge from each site promoted cross-site measurement uniformity with an extra layer of blindness.
Clinical Implications
This report complements the previous report of risperidone-induced improvement in children with autistic disorder and high irritability scores on a standardized scale. The effect was significant not only by standardized scale and by clinician-filtered impression, but also by individualized assessment of improvement in the problems parents were most concerned about. This confirms the clinical value of the treatment in such children. Table 3 , showing data for the different categories of parent-chosen symptoms, is of considerable clinical interest. It shows what kinds of things parents of such children are really concerned about, identifying the chief complaints for which they are requesting help. It also shows which kinds of symptoms are most likely to respond best to risperidone. For example, one can feel much more confident of helping a chief complaint of self-injury than helping a chief complaint of stereotypy with risperidone.
Additionally, this easily learned approach to eliciting and documenting chief complaints may be useful for clinicians to quantify severity and monitor treatment effects at the individual patient level.
In conclusion, risperidone, compared to placebo, was highly significantly effective in reducing the symptoms of most concern to parents of autistic children selected for aggression, irritability, and self-injury. Blind rating of quantified target symptoms identified by parents appears to be a sensitive, reliable, efficient, and consumer-friendly way to assess treatment effect, at least for externalizing behaviors. 
